<DOC>
	<DOCNO>NCT00001758</DOCNO>
	<brief_summary>This study continue treat collect safety efficacy data patient participate Glaxo-Wellcome 's multi-center study combination therapy abacavir , amprenavir efavirenz ( A Phase II Study Evaluating Safety Antiviral Activity Combination Therapy 1592U89 , 141W94 DMP 266 ( Sustiva ) HIV-1 Infected Subjects Detectable [ great 400 Copies/mL ] HIV-1 Plasma RNA Despite Treatment Protease Inhibitor-Containing Regimen ) . HIV-infected patient 18 year age older participate study NIH site may eligible current study . Participants follow every 3 month general health evaluation laboratory test . This NIH study , information provide Glaxo Wellcome</brief_summary>
	<brief_title>Continued Antiretroviral Therapy With Abacavir , Amprenavir Efavirenz</brief_title>
	<detailed_description>In open-label , single-arm study , HIV-1 infect patient , study entry , viral burden least 500 copies/mL despite 20 week treatment protease inhibitor receive combination therapy three antiretroviral agent investigational start study since approve : abacavir , amprenavir , efavirenz . At end 16 week , addition antiretroviral agent study regimen permit . This originally multi-center study , close site . It remain open NIH continue provide therapy subject receive benefit determined decline viral load baseline . Safety viral load data continue collect .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<criteria>INCLUSION/EXCLUSION CRITERIA : Subjects previously enrol protocol multicenter study sign new informed consent enrol . There new enrollment . Thus , subject previously enrol exclude . Subjects adults infect HIV1 , prior study enrollment , plasma viral load least 500 copies/mL despite least 20 week treatment protease inhibitor without change protease inhibitor therapy 12 week prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2003</verification_date>
	<keyword>Antiretroviral</keyword>
	<keyword>HIV-1</keyword>
	<keyword>1592U89</keyword>
	<keyword>141W94</keyword>
	<keyword>DMP 266</keyword>
</DOC>